These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12165074)

  • 1. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.
    Harris CL; Williams AS; Linton SM; Morgan BP
    Clin Exp Immunol; 2002 Aug; 129(2):198-207. PubMed ID: 12165074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
    Harris CL; Spiller OB; Morgan BP
    Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface.
    Zhang H; Lu S; Morrison SL; Tomlinson S
    J Biol Chem; 2001 Jul; 276(29):27290-5. PubMed ID: 11352906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex.
    Fodor WL; Rollins SA; Guilmette ER; Setter E; Squinto SP
    J Immunol; 1995 Nov; 155(9):4135-8. PubMed ID: 7594566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.
    Song H; He C; Knaak C; Guthridge JM; Holers VM; Tomlinson S
    J Clin Invest; 2003 Jun; 111(12):1875-85. PubMed ID: 12813023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
    FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of anti-complement "prodrugs": cleavable reagents for specific delivery of complement regulators to disease sites.
    Harris CL; Hughes CE; Williams AS; Goodfellow I; Evans DJ; Caterson B; Morgan BP
    J Biol Chem; 2003 Sep; 278(38):36068-76. PubMed ID: 12842884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.
    Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4195-202. PubMed ID: 11095615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delta-short consensus repeat 4-decay accelerating factor (DAF: CD55) inhibits complement-mediated cytolysis but not NK cell-mediated cytolysis.
    Miyagawa S; Kubo T; Matsunami K; Kusama T; Beppu K; Nozaki H; Moritan T; Ahn C; Kim JY; Fukuta D; Shirakura R
    J Immunol; 2004 Sep; 173(6):3945-52. PubMed ID: 15356143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
    Christiansen D; Loveland B; Kyriakou P; Lanteri M; Rubinstein E; Gerlier D
    Mol Immunol; 2000; 37(12-13):687-96. PubMed ID: 11275254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo.
    Hepburn NJ; Chamberlain-Banoub JL; Williams AS; Morgan BP; Harris CL
    Mol Immunol; 2008 Jan; 45(2):395-405. PubMed ID: 17651804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line.
    Varsano S; Kaminsky M; Kaiser M; Rashkovsky L
    Thorax; 2000 May; 55(5):364-9. PubMed ID: 10770816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue.
    Harrower TP; Richards A; Cruz G; Copeman L; Dunnett SB; Barker RA
    Xenotransplantation; 2004 Jan; 11(1):60-71. PubMed ID: 14962294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions.
    Harris CL; Lublin DM; Morgan BP
    J Immunol Methods; 2002 Oct; 268(2):245-58. PubMed ID: 12215393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo.
    Moran P; Beasley H; Gorrell A; Martin E; Gribling P; Fuchs H; Gillett N; Burton LE; Caras IW
    J Immunol; 1992 Sep; 149(5):1736-43. PubMed ID: 1380537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins.
    Gasque P; Thomas A; Fontaine M; Morgan BP
    J Neuroimmunol; 1996 May; 66(1-2):29-40. PubMed ID: 8964911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baculovirus GP64-pseudotyped HIV-based lentivirus vectors are stabilized against complement inactivation by codisplay of decay accelerating factor (DAF) or of a GP64-DAF fusion protein.
    Guibinga GH; Friedmann T
    Mol Ther; 2005 Apr; 11(4):645-51. PubMed ID: 15771967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64.
    Kaname Y; Tani H; Kataoka C; Shiokawa M; Taguwa S; Abe T; Moriishi K; Kinoshita T; Matsuura Y
    J Virol; 2010 Apr; 84(7):3210-9. PubMed ID: 20071581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.